en / es /
Consult our studies


Discover OWL Metabolomics contribution to scientific knowledge in our Resources section. We invite you to consult the publications in which we have participated, offering crucial insights into different therapeutic areas. Our library is here to help you with your research needs. We encourage you to explore our contributions with our extensive resources at your disposal. Use the filter options to search information by year of publication, therapeutic area, and/or disease.
Aging Andrology Basic science Cardiology Cardiovascular Dermatology Ecology Endocrinology Fertility Gastroenterology Gynecology Hepatology Inmunology Metabolomics Neuroscience Nutrition Oncology Ophtalmology
Acute myeloid leukemia Aging Alcoholic Hepatitis Alzheimer’s Disease Amyotrophic lateral sclerosis Andrology Atopic dermatitis Bile acid diarrhoea Cardiovascular disease Cholangiocarcinoma Chronic venous disease Cirrhosis Colorectal cancer Cushing syndrome DILI Diabetes Diet in gestation Ecology Fertility Fuchs endothelial dystrophy Glaucoma HIV Hepatitis C Hepatoblastoma Hepatocellular carcinoma Hypercholesterolemia Inflammation Intervertebral disc degeneration Lipodistrophy Liver fibrosis Membrane biophysics Metabolomics Multiple sclerosis NAFLD NASH Nutrition Obesity Ovarian endometriosis Pancreatic cancer Pancreatic ductal adenocarcinoma Parkinson’s Disease Pharmacometabolomics Primary sclerosing cholangitis Prostate cancer Schwann cell myelination T2DM Toxicity Vaccinia Virus Infection Vascular disease Wilson’s disease
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
Reset filters
Dietary and genetic disruption of hepatic methionine metabolism induce acid sphingomyelinase to promote steatohepatitis.
Redox Biol. 2023;59:102596. / 2023
Area: Gastroenterology / Hepatology
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.
Biomed Pharmacother. 2023;161:114535. / 2023
Area: Gastroenterology / Hepatology & Endocrinology
Disease: NAFLD/NASH and T2DM
Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
Lewinska M, et al. Gut 2023;72(9):1698-708. / 2023
Area: Gastroenterology / Hepatology
Disease: Bile acid diarrhoea
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
Hepatology 2022;76(6):1617-33. / 2022
Area: Oncology
Disease: Cholangiocarcinoma
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Gut 2002;71(5):1006-1019 / 2022
Area: Gastroenterology / Hepatology
One Carbon Metabolism and S-adenosylmethionine in Non-alcoholic Fatty Liver Disease Pathogenesis and Subtypes.
Livers 2022;2(4):243-57 / 2022
Area: Gastroenterology / Hepatology
Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.
Hepatology 2022;76(4):1121-34. / 2022
Area: Gastroenterology / Hepatology
Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
J Hepatol. 2022;77(1):15-28. / 2022
Area: Gastroenterology / Hepatology
Disease: Liver fibrosis
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
J Hepatol. 2022;76(4):800-11. / 2022
Area: Gastroenterology / Hepatology
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Front Pharmacol. 2022;13:827033. / 2022
Area: Gastroenterology / Hepatology & Endocrinology
Disease: NAFLD/NASH and T2DM
1 2 3 13
Our site uses cookies to collect information about your device and browsing activity. We use this data to improve the site, ensure security and deliver personalized content. You can manage your cookie preferences by clicking here.
Accept cookies Configure
Basic cookie information
This website uses cookies and/or similar technologies that store and retrieve information when you browse. In general, these technologies can serve very different purposes, such as, for example, recognizing you as a user, obtaining information about your browsing habits or personalizing the way in which the content is displayed. The specific uses we make of these technologies are described below. By default, all cookies are disabled, except for technical ones, which are necessary for the website to function. If you wish to obtain more information or exercise your data protection rights, you can consult our "Cookie Policy".
Accept cookies Configure
Technical and/or necessary cookies Always active
Technical cookies are those that facilitate user navigation and the use of the different options or services offered by the website, such as identifying the session, allowing access to certain areas, facilitating orders, purchases, filling out forms, registrations, security, facilitating functionalities. (videos, social networks...).
Analysis cookies
Analysis cookies are those used to carry out anonymous analysis of the behavior of web users and that allow user activity to be measured and navigation profiles to be created with the objective of improving websites.
Confirm preferences
Linkedin Twitter
By Rubió
Carrer Indústria 29, Polígon Industrial Comte de Sert 08755
Castellbisbal, Barcelona (España), +34 937 722 509labrubio@labrubio.com